- Nano cap Cesca Therapeutics (KOOL +26.2%) shows bullish price action with today's up move on a 10x surge in volume. It represents a successful retest of the January 21 breakout when prices popped 111% on massive turnover of 32.9M shares after the company announced positive Phase 1b clinical trial results for its stem cell therapy for critical limb ischemia.
- The company acquired development partner TotipotentRX shortly thereafter and changed its name from Thermogenesis.
- Last month, it submitted a pre-IDE information package to the FDA for the product, now called SurgWerks, as the first step in its commercialization efforts in the U.S.
- Considering its microscopic market cap of $66M, retail investors should insist on thorough due diligence before considering deploying capital.
- Corporate presentation
From other sites
CESCA THERAPEUTICS : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)at 4-traders.com (Mon, 5:32PM)
at 4-traders.com (Mon, 4:04PM)
at 4-traders.com (Mon, 6:16AM)
at Benzinga.com (Jan 2, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs